2021/4/13

• Otsuka and Lundbeck announce decision to continue phase III clinical trial evaluating brexpiprazole for treatment of agitation in patients with Alzheimer's-type dementia (198KB)

2021/3/30

• Otsuka and Akebia Announce Submission of New Drug Application to the FDA for Approval of Akebia’s Vadadustat
  (144KB)

2021/3/30

• Otsuka Holdings appoints Board Members and Audit & Supervisory Board Members (147KB)

2021/3/30

• Notice Concerning Disposal of Treasury Shares as Restricted Stock Compensation (163KB)

2021/2/12

• Notice of Change of Certified Public Accountant (161KB)

2021/2/12

• Otsuka Holdings announces FY2020 financial results

2021/2/9

• Office Divisions of Five Otsuka Group Companies
  to Switch to Green Power (102KB)

2020/12/17

• Otsuka Health Comic Library Celebrates 30 Years
  Revamped website aims to further contribute to children’s health (233KB)

2020/12/10

• Otsuka Announces Results of Two International Clinical Studies in Patients with Treatment Resistant Hypertension and Breakthrough Device Designation for Paradise Ultrasound Renal Denervation System for Uncontrolled Hypertension (127KB)

2020/9/30

• Otsuka Group Acquires ISO 14001 Certification
  -Reinforcement of group-wide environmental initiatives- (291KB)

2020/9/25

• Otsuka’s ABILIFY MAINTENA approved for the additional indication of bipolar I disorder in Japan (83KB)

2020/9/3

• Top-line Results from Global Phase 3 Program of Vadadustat, a Drug Candidate for Treatment of Renal Anemia due to Chronic Kidney Disease in Non-Dialysis Patients (140KB)

2020/5/5

• Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis (32KB)

2020/4/24

• Notice Concerning Completion of Payment for Disposal of Treasury Shares as Restricted Stock Compensation
  (43KB)

2020/4/20

• Notice regarding Postponement of the Announcement of Consolidated Financial Results for FY2020 First Quarter (23KB)

2020/3/27

• Notice Concerning Disposal of Treasury Shares as Restricted Stock Compensation (84KB)

2020/3/27

• Otsuka Holdings appoints Board Members and Audit & Supervisory Board Members (192KB)

2020/3/11

• Otsuka Chemical Announces Personnel Changes (187KB)

2020/2/14

• Otsuka Holdings Announces Personnel Changes (193KB)

2019/12/11

• Announcement of Changes in Company Officers at Otsuka Pharmaceutical Co., Ltd. (125KB)

2019/11/12

• Otsuka Pharmaceutical and Avanir Pharmaceuticals to Continue Clinical Development of Investigational AVP-786 for the Treatment of Agitation in Patients with Alzheimer’s Dementia (84KB)

2019/9/27

• Otsuka's Subsidiary Avanir Pharmaceuticals Reports Top-line Data from Second Phase 3 Trial Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia (79KB)

2019/9/26

• Otsuka Applies for the Additional Indication in Japan of Bipolar Disorder for ABILIFY MAINTENA for Suspended Release Injectable Suspension (63KB)

2019/8/22

• Otsuka Group Adopts CO2-free Electricity
  Annual CO2 Emissions to Decline by Approximately 9% (193KB)

2019/7/30

• Notice concerning amendments to the forecasts for the first half of FY2019 (88KB)

2019/6/18

• Otsuka Electronics Announces Personnel Changes (96KB)

2019/5/30

• Otsuka announces the Third Medium-Term Management Plan (65KB)

2019/5/20

• Notice Concerning Completion of Payment for Disposal of Treasury Shares as Restricted Stock Compensation
  (86KB)

2019/4/15

• Notice Regarding Company Split (Simplified Absorption–type Company Split) (105KB)

2019/4/12

• Notice Concerning Disposal of Treasury Shares as Restricted Stock Compensation (83KB)

2019/3/28

• Otsuka Holdings appoints Board Members and Audit & Supervisory Board Members (194KB)

2019/3/25

• Otsuka’s Subsidiary Avanir Pharmaceuticals Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer’s Dementia (138KB)

2019/3/11

• Otsuka Chemical Announces Personnel Changes (197KB)

2019/2/15

• Otsuka and Lundbeck report phase III data evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder (56KB)

2019/2/13

• Otsuka Holdings Announces Personnel Changes (186KB)

2019/2/13

• Notice of Introduction of Restricted Stock Compensation Plan (58KB)

2018/9/12

• Notice Regarding Company Split (Simplified Absorption–type Company Split) (137KB)

2018/9/3

• Otsuka Pharmaceutical Completes Acquisition of Visterra (84KB)

2018/9/3

• Otsuka Pharmaceutical Completes Acquisition of Visterra

2018/7/31

• Notice concerning amendments to the forecasts (IFRS) for the first half of FY2018
  (88KB)

2018/7/31

• Otsuka and Lundbeck’s Rxulti® (brexpiprazole) approved by the European Commission (82KB)

2018/7/11

• Otsuka Pharmaceutical to Acquire Visterra (127KB)

2018/7/10

• Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement

2018/6/4

• Otsuka and Lundbeck’s Rxulti® (brexpiprazole) receives positive opinion in EU from CHMP for the treatment of schizophrenia in adults. (192KB)

2018/5/24

• Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease (88KB)

2018/4/25

• Otsuka's JYNARQUE™ (tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD) (123KB)

2018/4/18

• REXULTI® Tablets, a New Antipsychotic Drug, Launched in Japan (81KB)

2018/3/29

• Otsuka Holdings appoints Board Members and Audit & Supervisory Board Members (161KB)

2018/3/20

• Otsuka Pharmaceutical Factory enters into an agreement to acquire additional equity in its joint venture subsidiary, Otsuka Pharmaceutical India Private Limited, making it a wholly owned subsidiary
  (94KB)

2018/2/14

• Otsuka Holdings Announces Personnel Changes (162KB)

2018/2/8

• Notice concerning amendments to financial forecasts for FY 2017 (87KB)

2018/1/19

• Otsuka Signs Statement of Support for Women’s Empowerment Principles (218KB)

2018/1/19

• Otsuka Receives Approval in Japan for the Manufacture and Sale of New Antipsychotic Drug Rexulti Tablets for Schizophrenia
  (57KB)

2017/11/14

• Notice Regarding Company Split (Simplified Absorption–type Company Split) (212KB)

2017/11/9

• U.S. FDA Accepts Otsuka’s Resubmission to Support a Regulatory Review of Tolvaptan in the Treatment of ADPKD (221KB)

2017/11/6

• Otsuka Announces Phase 3 Results for Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (98KB)

2017/11/1

• Otsuka and Lundbeck will Initiate a Third Phase 3 Trial to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type (149KB)

2017/10/12

• Otsuka and Lundbeck Announce Initiation of Two Phase 3 Trials of Brexpiprazole in Patients with Bipolar I Disorder (81KB)

2017/9/21

• Otsuka Pharmaceutical Factory completes acquisition of additional equity in its joint venture subsidiary, Otsuka Pharmaceutical India Private Limited (139KB)

2017/9/1

• Otsuka Pharmaceutical Completes Acquisition of Daiya (88KB)

2017/7/31

• ABILIFY MAINTENA® (aripiprazole) for Extended-Release Injectable Suspension Approved by U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder (66KB)

2017/7/27

• Otsuka Pharmaceutical to Acquire Daiya,
  a Rapidly Growing Plant-Based Food Company in North America
  (229KB)

2017/5/22

• Otsuka Announces Results of Phase 3 Data on Tolvaptan
  Under Development for ADPKD in U.S. (103KB)

2017/5/8

• Otsuka Pharmaceutical Factory,
  enters into an agreement to acquire additional equity in its joint venture subsidiary, Otsuka Pharmaceutical India Private Limited (OPI) (141KB)

2017/5/2

• Otsuka and Lundbeck Announce Results of Brexpiprazole
  on Symptoms of Agitation Related to Alzheimer's-type Dementia (96KB)

2017/3/30

• Otsuka Holdings appoints Board Members and Audit & Supervisory Board Members (161KB)

2017/3/24

• Lundbeck and Otsuka’s brexpiprazole for adult patients with schizophrenia accepted for review by EMA (84KB)

2017/2/14

• Otsuka Holdings Announces Personnel Changes (110KB)

2017/1/6

• Otsuka Submits New Drug Application in Japan for Brexpiprazole in the Treatment of Schizophrenia (77KB)

2016

2016/12/20

• JSC High Performance Center Total Conditioning Research Project
  Joint research aims to promote sports medicine and science and boost international competitiveness (194KB)

2016/12/1

• FDA Accepts For Review A Supplemental New Drug Application To Expand Labeling Of Abilify Maintena® (aripiprazole) For The Treatment Of Bipolar I Disorder (109KB)

2016/11/25

• Otsuka Joins UN Global Compact (170KB)

2016/11/24

• Otsuka Pharmaceutical Enters into Cooperative Agreements with Hokkaido Government Entities
  - Partnership Agreement for Promotion of Hokkaido Residents’ Health Initiatives -
  - Cooperative Accord for Children’s Education and Sports Promotion -

2016/11/11

• Notice Concerning Voluntary Adoption of
  International Financial Reporting Standards (IFRS) (129KB)

2016/8/5

• Notice Regarding Completion of Share Transfer of an Affiliated Company Accounted for by the Equity Method (39KB)

2016/7/29

• Notice concerning amendments to the forecasts for the first half of FY2016 (107KB)

2016/6/1

• Determination of Final Terms of Share Remuneration-type Stock Options (Share Acquisition Rights) (66KB)

2016/5/31

• Otsuka Holdings Announces New, Additional Certification Under “ISO 22301”, the International Standard for Business Continuity Management (168KB)

2016/5/17

• Notification of Change of Equity Method Affiliate (Transfer of Shares) (161KB)

2016/5/16

• Otsuka Holdings Announces Collaboration with ReCor Medical for Commercialization of ReCor Medical’s Ultrasound Renal Denervation Technology in Asia (145KB)

2016/5/13

• Issuance of Share Remuneration-type Stock Options (Share Acquisition Rights) (79KB)

2016/3/30

• Otsuka Holdings appoints Board Members and Audit & Supervisory Board Members (166KB)

2016/2/12

• Notice Regarding the Partial Amendment of Articles of Incorporation (98KB)

2016/2/12

• Introduction of Share Remuneration-type Stock Options (Share Acquisition Rights) (158KB)

2016/2/12

• Otsuka Holdings Announces Personnel Changes (111KB)

2015

2015/12/7

• Otsuka Files for Approval in Japan for an Additional Indication for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism (109KB)

2015/7/30

• Notice concerning amendments to the forecasts for the first half of FY2015 (87KB)

2015/7/11

• U.S. FDA APPROVES OTSUKA AND LUNDBECK’S REXULTI® (BREXPIPRAZOLE) AS ADJUNCTIVE TREATMENT FOR ADULTS WITH MAJOR DEPRESSIVE DISORDER AND AS A TREATMENT FOR ADULTS WITH SCHIZOPHRENIA (181KB)

2015/4/30

• Otsuka announces 2015 first quarter U.S. net sales figures of ABILIFY® (108KB)

2015/3/27

• Otsuka Holdings Announces Change in Status of Representative Director (125KB)

2015/3/26

• Otsuka Granted Approval in Japan for a New Formulation of ABIILIFY – ABILIFY for Extended–release Injectable Suspension, for Intramuscular Use – Indicated for Schizophrenia (136KB)

2015/2/27

• Otsuka Pharmaceutical Receives Princess Chichibu Memorial Award for Distinguished Service to Tuberculosis Elimination (128KB)

2015/2/26

• TAKECAB® Now Available for the Treatment of Acid-related Diseases in Japan (105KB)

2015/2/13

• Otsuka Holdings Announces Personnel Change of Representative Director (124KB)

2015/2/12

• Notice of Change of Representative Director of Otsuka Pharmaceutical Co Ltd(Concurrent Obituary） (97KB)

2015/1/28

• Otsuka announces 2014 fourth quarter U.S. net sales figures of ABILIFY® (108KB)

2015/1/13

• Otsuka Pharmaceutical Completes Acquisition of Avanir Pharmaceuticals (119KB)

2015/1/8

• Terminations of Otsuka’s Contract With OncoTherapy Science, Inc. on a Candidate Therapeutic Vaccine For Pancreatic Cancer and Otsuka’s Sublicensing Contract With Fuso Pharmaceutical Industries for the Marketing of a Candidate Therapeutic Vaccine, OTS102 (109KB)

2015/1/5

• Otsuka Holdings Announces Expiration of HSR Waiting Period for Avanir Tender Offer (96KB)

2014

2014/12/26

• New Drug Application Approval of TAKECAB® for the treatment of Acid-related Diseases in Japan (101KB)

2014/12/13

• Otsuka Pharmaceutical Commences Tender Offer to Acquire All Outstanding Shares of Avanir Pharmaceuticals (196KB)

2014/12/11

• OTSUKA AND LUNDBECK’S BREXPIPRAZOLE DEMONSTRATES STATISTICALLY SIGNIFICANT EFFECTS IN NEW PHASE III STUDIES IN ADULT PATIENTS WITH SCHIZOPHRENIA PRESENTED AT THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING (130KB)

2014/12/10

• OTSUKA AND LUNDBECK PRESENT PHASE III DATA ON BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN ADULT PATIENTS WITH MAJOR DEPRESSION AT THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING (127KB)

2014/12/8

• U.S. FDA APPROVES THE LABELING UPDATE OF ABILIFY MAINTENA® (ARIPIPRAZOLE) FOR EXTENDED-RELEASE INJECTABLE SUSPENSION TO DESCRIBE NEW CLINICAL DATA FOR THE TREATMENT OF ACUTELY RELAPSED ADULTS WITH SCHIZOPHRENIA (116KB)

2014/12/2

• Otsuka Pharmaceutical to Acquire Avanir Pharmaceuticals
  Full-scale entry to neurologic diseases area widens core business presence in CNS (222KB)

2014/12/1

• Notice of Change of Representative Director (Obituary) (86KB)

2014/11/19

• Otsuka Holdings’ Chairman and Representative Director Akihiko Otsuka receives the “Legion d’honneur” from France (104KB)

2014/10/27

• Otsuka announces 2014 third quarter U.S. net sales figures of ABILIFY® (108KB)

2014/9/24

• U.S. FDA ACCEPTS OTSUKA AND LUNDBECK’S FILING FOR REVIEW OF BREXPIPRAZOLE FOR THE TREATMENT OF SCHIZOPHRENIA AND AS ADJUNCTIVE THERAPY FOR THE TREATMENT OF MAJOR DEPRESSION (143KB)

2014/8/26

• Otsuka Holdings announces Second Medium-Term Management Plan (183KB)

2014/7/25

• Otsuka announces 2014 second quarter U.S. net sales figures of ABILIFY® (108KB)

2014/7/14

• OTSUKA AND LUNDBECK SUBMIT NEW DRUG APPLICATION IN THE US FOR BREXPIPRAZOLE FOR THE TREATMENT OF SCHIZOPHRENIA AND AS ADJUNCTIVE THERAPY FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (110KB)

2014/5/14

• Notice Regarding the Partial Amendment of Articles of Incorporation (104KB)

2014/5/14

• Otsuka Holdings Announces Personnel Changes of Representative Director, Directors and Audit & Supervisory Board Members (90KB)

2014/5/14

• Notice Regarding Differences between Non-Consolidated Actual Results for the Fiscal Year Ended March 31, 2013 and Fiscal Year Ended March 31, 2014 (63KB)

2014/4/30

• Otsuka announces 2014 first quarter U.S. net sales figures of ABILIFY® (103KB)

2014/3/27

• Otsuka and Takeda Announce a Co-promotion Agreement in Japan of TAK-438 for the Treatment of Acid-related Diseases in the Gastrointestinal Therapeutic Area (119KB)

2014/3/3

• INVESTIGATIONAL COMPOUND BREXPIPRAZOLE MET PRIMARY AND SECONDARY STUDY ENDPOINTS IN PHASE III CLINICAL TRIAL IN MAJOR DEPRESSIVE DISORDER (MDD) (46KB)

2014/1/27

• Otsuka announces 2013 fourth quarter U.S. net sales figures of ABILIFY® (60KB)

2014/1/24

• Otsuka and Lundbeck to present new data on brexpiprazole in major depressive disorder (MDD) at European Psychiatry Association 2014 Congress (107KB)

2014/1/15

• Otsuka Pharmaceutical Submits Marketing Authorization Application in Japan for Abilify Once-Monthly Injectable Form for the Treatment of Schizophrenia (117KB)

2013

2013/11/21

• Otsuka and Lundbeck's Once-Monthly Abilify Maintena® (Aripiprazole) Now Approved in Europe for Maintenance Treatment of Schizophrenia in Adult Patients Stabilized with Oral Aripiprazole (154KB)

2013/11/14

• Otsuka Foods Announces Personnel Changes (123KB)

2013/11/13

• Notice Regarding Change in Business Year (45KB)

2013/11/13

• Otsuka Holdings Announces Personnel Changes (135KB)

2013/10/24

• Otsuka announces 2013 third quarter U.S. net sales figures of ABILIFY® (65KB)

2013/10/11

• Otsuka Pharmaceutical Completes Acquisition of Astex Pharmaceuticals (143KB)

2013/10/7

• Otsuka Holdings Announces Expiration of HSR Waiting Period
  for Astex Tender Offer (95KB)

2013/9/14

• Otsuka Pharmaceutical Commences Tender Offer to Acquire All Outstanding Shares of Astex Pharmaceuticals
  (101KB)

2013/9/5

• Otsuka Pharmaceutical to Acquire Astex Pharmaceuticals (265KB)

2013/7/29

• Otsuka Techno Takes an Equity Interest in a Chinese Firm That Manufactures and Markets Plastic Caps for I.V. Solution-related Products (144KB)

2013/7/26

• Otsuka announces 2013 second quarter U.S. net sales figures of ABILIFY® (133KB)

2013/6/20

• Otsuka Medical Devices Loans MicroPort to Support its Acquisition of Wright Medical’s Hips and Knee Implant Business (123KB)

2013/6/19

• Otsuka Holdings Announces Completion of Share Repurchase (105KB)

2013/6/14

• A New Choice of Therapy for the Treatment of Depression:
  ABILIFY® Granted Additional Approval as Adjunctive Therapy for the Treatment of Depression in Japan (109KB)

2013/6/4

• Notice regarding Status of Acquisition of Own Shares (96KB)

2013/5/22

• Otsuka Pharmaceutical Factory and Fresenius Kabi Japan enter into an exclusive distribution agreement of HES products, including the newly approved Voluven 6% (127KB)

2013/5/16

• Notice of the Result of Share Repurchase through ToSTNeT-3 (104KB)

2013/5/15

• Notice of Acquisition of Own Shares through ToSTNeT-3 (102KB)

2013/5/14

• Otsuka Holdings Announces Personnel Changes (113KB)

2013/5/14

• Otsuka Holdings Co., Ltd. to Acquire Own Shares (122KB)

2013/4/26

• Otsuka announces 2013 first quarter U.S. net sales figures of ABILIFY® (129KB)

2013/3/26

• Lundbeck and Otsuka Further Expand Alliance and Enter Into Collaboration For the Development and Commercialization of Lu AE58054 In Development For Alzheimer’s Disease (243KB)

2013/3/25

• Otsuka Obtains Marketing Approval in Japan for Onglyza® Tablets to Treat Type 2 Diabetes; Transferred Rights to Kyowa Hakko Kirin (117KB)

2013/3/1

• FDA Approves Once-Monthly ABILIFY MAINTENA™ (Aripiprazole) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia (257KB)

2013/1/25

• Otsuka announces 2012 fourth quarter U.S. net sales figures of ABILIFY® (129KB)

2012

2012/12/25

• Otsuka and Lundbeck initiate the regulatory process for aripiprazole (once-monthly) depot formulation in Europe (150KB)

2012/12/7

• Establishment of Joint Venture Company (Subsidiary) in India (159KB)

2012/10/29

• Otsuka Medical Devices and Pioneer Form
  an Alliance in the Medical Endoscope Business (411KB)

2012/10/25

• Otsuka announces 2012 third quarter U.S. net sales figures of ABILIFY® (131KB)

2012/9/12

• Otsuka and Lundbeck Announce U.S. Food and Drug Administration Acknowledges Receipt of Resubmission of New Drug Application for Aripiprazole Depot Formulation (145KB)

2012/9/3

• ABILIFY®,The First Antipsychotic Agent in Japan
  Applying for Adjunctive Treatment in Major Depressive Disorder (156KB)

2012/7/30

• Otsuka Holdings Announces Completion of Share Repurchase (83KB)

2012/7/27

• OTSUKA RECEIVES COMPLETE RESPONSE LETTER FOR EXTENDED-RELEASE INJECTABLE SUSPENSION OF ARIPIPRAZOLE (127KB)

2012/7/26

• Otsuka announces 2012 second quarter U.S. net sales figures of ABILIFY® (126KB)

2012/7/13

• Otsuka Holdings Announces Personnel Changes (Resignation) of Representative Director (84KB)

2012/7/3

• Notice regarding Status of Acquisition of Own Shares (111KB)

2012/6/29

• Otsuka Pharmaceutical and Kyowa Hakko Kirin announce strategic alliance in the fields of diabetes and oncology (175KB)

2012/6/15

• Notice of the Result of Share Repurchase through ToSTNeT-3 (82KB)

2012/6/14

• Notice of Acquisition of Own Shares through ToSTNeT-3 (83KB)

2012/6/13

• Otsuka Holdings Co., Ltd. to Acquire Own Shares (102KB)

2012/5/11

• Otsuka Holdings Announces Personnel Changes (180KB)

2012/5/8

• Results from a Phase 3 Study of Once-monthly Aripiprazole Intramuscular (IM) Depot Formulation for the Maintenance Treatment of Schizophrenia Presented at APA Annual Meeting (197KB)

2012/4/27

• Otsuka announces 2012 first quarter U.S. net sales figures of ABILIFY® (126KB)

2012/3/13

• Otsuka America Announces Personnel Changes (182KB)

2012/1/27

• Otsuka announces 2011 fourth quarter U.S. net sales figures of ABILIFY® (58KB)

2012/1/18

• Antipsychotic Agent ABILIFY® Receives Regulatory Approvals for Additional Indication "Improvement of Manic Symptoms Associated with Bipolar Disorder" and for New Dosage Form "ABILIFY® OD Tablets" (267KB)

2012/1/13

• Otsuka Pharmaceutical and UCB
  focus collaboration in the area of Central Nervous System (CNS) disorders (51KB)

2011

2011/12/26

• Otsuka Medical Device Enters Endoscopic Field by Acquiring Stake in Italy’s Era Endoscopy S.r.l., An Innovator in Self-propelled Robotic Colonoscopy (142KB)

2011/12/14

• Otsuka Techno to Construct New Factory at Industrial Park in Naruto, Tokushima (267KB)

2011/12/12

• Otsuka Chemical Announces Personnel Changes (297KB)

2011/12/12

• Taiho Pharmaceutical Announces Personnel Changes (280KB)

2011/11/28

• J.O. Pharma Co., Ltd. to construct a new manufacturing facility for
  prefilled syringes (a syringe with injectable drug solution filled in advance): Signing of an agreement with Shimane Prefecture and Izumo City
  for the facility construction (264KB)

2011/11/22

• NEW DRUG APPLICATION FOR OTSUKA’S ONCE-MONTHLY ARIPIPRAZOLE DEPOT FORMULATION FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH SCHIZOPHRENIA ACCEPTED FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION (47KB)

2011/11/11

• OTSUKA PHARMACEUTICAL CO., LTD. AND H. LUNDBECK A/S Sign Historic Agreement to Deliver Innovative Medicines with Focus on Psychiatric Disorders Worldwide (109KB)

2011/10/31

• Notice concerning amendments to the forecasts for the first half of FY2011 (46KB)

2011/10/28

• Otsuka announces 2011 third quarter U.S. net sales figures of ABILIFY® (63KB)

2011/10/19

• Otsuka Pharmaceutical Factory and Living Cell Technologies Limited Agree to Establish Joint Venture to Develop and Commercialize Pancreatic Islets as a Treatment for Diabetes (217KB)

2011/10/17

• Otsuka Medical Devices Acquires KiSCO Medical Group,
  Enters the Field of Orthopedic Surgery (126KB)

2011/7/29

• Otsuka announces 2011 second quarter U.S. net sales figures of ABILIFY® (63KB)

2011/7/21

• Taiho Pharmaceutical Co., Ltd. and Nordic Group BV Enter into a Development and Commercialization Agreement for the recently EMA approved Anti-Cancer Drug Teysuno™ covering the EU and other Selected European Countries (70KB)

2011/6/10

• Otsuka Warehouse Announces Personnel Changes (99KB)

2011/6/10

• Otsuka Chemical Announces Personnel Changes (112KB)

2011/5/16

• Otsuka Holdings Formulates First Medium-Term Management Plan (64KB)

2011/5/16

• OTSUKA PHARMACEUTICAL CO., LTD. ANNOUNCES RESULTS FROM A PHASE 2 STUDY OF INVESTIGATIONAL PRODUCT OPC-34712 AS ADJUNCTIVE THERAPY IN ADULTS WITH MAJOR DEPRESSIVE DISORDER (54KB)

2011/5/2

• Otsuka announces 2011 first quarter U.S. net sales figures of ABILIFY® (63KB)

2011/4/13

• Announcement of License Agreement on a New Antiemetic Combination Agent (Taiho Pharmaceutical) (114KB)

2011/4/12

• OTSUKA PHARMACEUTICAL FACTORY INVESTS IN LIVING CELL TECHNOLOGIES LIMITED,
  A BIOTECHNOLOGY COMPANY ADVANCING DEVELOPMENT OF ENCAPSULATED PORCINE PANCREATIC ISLET REPLACEMENT TREATMENT (196KB)

2011/3/31

• Notice Regarding Effects of the Tohoku Pacific Offshore Earthquake (3) (118KB)

2011/3/28

• EN Otsuka Pharmaceutical Announces Changes to Board Members (161KB)

2011/3/25

• Announcement of Promotion of Managing Director (Taiho Pharmaceutical) (150KB)

2011/3/22

• Notice Regarding Support in Response to the Tohoku Pacific Offshore Earthquake (114KB)

2011/3/16

• Notice Regarding Effects of the Tohoku Pacific Offshore Earthquake (2) (28KB)

2011/3/15

• TEYSUNO™ (S-1) RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR ADVANCED GASTRIC CANCER (48KB)

2011/3/14

• Notice Regarding Effects of the Tohoku Pacific Offshore Earthquake (29KB)

2011/3/7

• Otsuka Pharmaceutical Announces Changes to Board Members (62KB)

2011/3/3

• Day Care Center for Children
  BeanStalk Kids Center TOKUSHIMA
  Opening April 1, 2011

2011/2/18

• ABILIFY® (aripiprazole) Approved for Maintenance Treatment of Bipolar I Disorder as an Adjunct to Either Lithium or Valproate (111KB)

2011/2/16

• Otsuka Foods and Otsuka Pharmaceutical to Partner with ITO EN on Cross-Sales of Products in Vending Machines (419KB)

2011/2/14

• Otsuka Holdings Announces Establishment of a Subsidiary and Company Splits (Short-Form Absorption-Type Splits) to Reorganize Its Medical Devices Business (92KB)

2011/2/14

• Financial Results for 3Q/FY2010 (238KB)

2011/2/3

• Otsuka Holdings Co., Ltd. Obtains Credit Rating (39KB)

2011/2/1

• Otsuka Announces Initiation of Phase II Clinical Trials for Angiogenesis Inhibitor OCV-101 (39KB)

2011/1/31

• Nutraceutical Business in Europe Moves to New Stage SOYJOY, the First Japanese Product, Set to Debut in 4 Countries

2011/1/28

• Otsuka announces 2010 U.S. net sales figures of ABIFILY® (37KB)

2011/1/24

• Otsuka Pharmaceutical Files for Additional Indication Regulatory Approval in Japan for ABILIFY®, a Treatment for the Manic Symptoms Associated with Bipolar Disorder

2010

2010/12/27

• Notice Concerning Loan Transaction Stocks Assignment (26KB)

2010/12/16

• Defendants Appeal From Final Judgment in U.S. Abilify® Patent Litigation (67KB)

2010/12/15

• Otsuka Holdings listed on the First Section of the Tokyo Stock Exchange (41KB)

2010/12/15

• Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2011 [Japan GAAP] (224KB)

2010/11/16

• Otsuka Prevails in U.S. Abilify® Patent Litigation (94KB)

2010/6/29

• Otsuka Holdings Co., Ltd. Appoints the Board Members and Statutory Auditors (141KB)

2010/5/14

• Fiscal Year through March 2010 – Consolidated Results (707KB)

2009

2009/11/13

• Otsuka Holdings announces “Research and Development” website opens on November 13, 2009 (500KB)

2009/10/9

• Otsuka Holdings receives the 2009 Investor in France Award on October 8, 2009 (140KB)

2009/5/15

• Fiscal Year through March 2009 – Consolidated Results (353KB)

2009/5/8

• Announcement regarding the conversion of Otsuka Chemical Holdings into a wholly owned subsidiary of Otsuka Holdings

2008

2008/12/24

• Otsuka Pharmaceutical Co., Ltd. to acquire Nutrition & Santé, the European market leader in functional and dietetic foods

2008/8/20

• Otsuka Holdings Co., Ltd. Appoints the Board Members

2008/7/25

• Notice of the Reorganization of Three Otsuka Group Companies(Otsuka Pharmaceutical Factory, Otsuka Warehouse, and Taiho Pharmaceutical) as Wholly Owned Direct Subsidiaries

2008/7/8

• Tatsuo Higuchi Appointed as President, Representative Director of Otsuka Holdings Co., Ltd.

2008/7/8

• Establishment of Otsuka Holdings Co., Ltd.